Company Overview
Snapshot
Founded in January 2023 by Raviv Pryluk, Dan Goldstaub, and Elad Berkman, PhaseV has grown to 11–50 employees. The company has raised $65 million across two funding rounds from six investors. In May 2025, PhaseV secured a significant Series A funding round.
Business overview
PhaseV develops a platform designed to optimize clinical trials through adaptive design and closed-loop execution. The company leverages an intuitive user interface, flexible software architecture, and cutting-edge algorithms, including reinforcement learning and causal machine learning, to support critical clinical decisions throughout the trial process. PhaseV operates within the Health Tech & Life Sciences sector, specifically focusing on Digital Healthcare and Clinical Workflow solutions.
Strategic signal
In March 2026, PhaseV launched its AI Conductor, a centralized platform aimed at automating clinical workflows from protocol to submission. This development signals a strategic move towards enhancing efficiency and reducing manual intervention in clinical development, positioning PhaseV as a key innovator in applying AI to streamline complex pharmaceutical processes.
Log in to access full profile ›Company Intelligence Q&A
- What was the most recent significant funding event for PhaseV?
- In May 2025, PhaseV completed a Series A funding round, raising $50 million. This round was co-led by Accel and Insight Partners.
- What is PhaseV's AI Conductor?
- PhaseV launched its AI Conductor in March 2026. This platform automates clinical workflows from protocol design through submission, centralizing and streamlining various stages of clinical development.
- Has PhaseV formed any notable partnerships recently?
- In May 2025, PhaseV announced a strategic partnership with the Crohn's & Colitis Foundation to advance Inflammatory Bowel Disease (IBD) research using AI/ML-driven clinical development.
- What new platform capabilities did PhaseV unveil in 2024?
- In September 2024, PhaseV unveiled the latest capabilities of its AdaptV platform, which uses machine learning to improve oncology clinical trials.
- When was PhaseV founded and by whom?
- PhaseV was founded in January 2023 by co-founders Raviv Pryluk, Dan Goldstaub, and Elad Berkman.